Clinical Trial Update: Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating carfilzomib and TGR-1202 in relapsed/refractory lymphoma and Hodgkin disease, terminated with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Carfilzomib (carfilzomib)
• TGR-1202 (umbralisib)

Snippet

Sponsor: Columbia University | Conditions: Hodgkin Disease, Lymphoma, Non-hodgkin | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-07-16